Inhibition of TNFα production and blocking of mitogen-activated protein kinase/NFκB activation in lipopolysaccharide-induced thp-1 human monocytes by 3-o-acetyl-11-keto-β-boswellic acid

Krishanu Sengupta, Trimurtulu Golakoti, Ajit K. Marasetti, Tejaswi Tummala, Suryachandra R. Ravada, Alluri V. Krishnaraju, Siba P Raychaudhuri

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Boswellia serrata resin is regarded as a potent anti-inflammatory agent in traditional and herbal medicine in the Indian subcontinent. The compound 3-O-acetyl-11-keto-β-boswellic acid (AKBA) is the most effective boswellic acid and mostly responsible for B. serrata's anti-inflammatory properties. Here, we reexamined the anti-inflammatory potential of a product selectively enriched with 30% AKBA (BE-30, also known as 5-Loxin®) and evaluated its underlying possible molecular mechanism of action. BE-30 was 42.96% more effective than regular Boswellia extract (BE-3) in inhibiting 5-lipoxygenase activity. In lipopolysaccharide (LPS)-induced THP-1 human monocytes, BE-30 showed a strong anti-TNFα activity (half maximal inhibitory concentration 4.61 ± 0.87 ̄g/mL), which provides 71.14% (P < 0.001) better efficacy than BE-3. Our investigations suggest that BE-30 inhibits the LPS-induced activation of serine/threonine kinases of mitogen-activated protein kinase family, which are the key players responsible for a variety of cellular responses, including inflammation. Additionally, we also show that BE-30 blocks the LPS-induced NFκB activation by inhibiting IκBα phosphorylation and p65 translocation to the nuclear compartment of THP-1 monocytes. Collectively, these findings provide molecular basis for the anti-inflammatory properties of BE-30. PRACTICAL APPLICATIONS This article describes the underlying molecular mechanisms for the anti-inflammatory activities of an enriched formulation containing up to 30% 3-O-acetyl-11-keto- β-boswellic acid (AKBA), the active principle that is mainly responsible for Boswellia serrata's anti-inflammatory properties. This AKBA-enriched formulation (BE-30), known as 5-Loxin, is commercially available in the United States and is being used as a key ingredient of several formulations for improvement of joint health. This work explains anti-TNFα properties of BE-30 in a cellular inflammation model in vitro and its inhibitory action on MAPK pathways in inflammation and, in addition, its anti-NFκB activities. The findings will provide a further comprehensive mechanism of anti-inflammatory action of 5-Loxin at the cellular and molecular level.

Original languageEnglish (US)
Pages (from-to)325-344
Number of pages20
JournalJournal of Food Lipids
Volume16
Issue number3
DOIs
StatePublished - Aug 2009

Fingerprint

keto acids
Mitogen-Activated Protein Kinases
anti-inflammatory activity
mitogen-activated protein kinase
monocytes
lipopolysaccharides
Lipopolysaccharides
Monocytes
Anti-Inflammatory Agents
Chemical activation
Boswellia
Boswellia serrata
inflammation
Inflammation
anti-inflammatory agents
mitogen-activated protein kinase kinase
herbal medicines
lipoxygenase
traditional medicine
threonine

ASJC Scopus subject areas

  • Food Science
  • Chemistry(all)

Cite this

Inhibition of TNFα production and blocking of mitogen-activated protein kinase/NFκB activation in lipopolysaccharide-induced thp-1 human monocytes by 3-o-acetyl-11-keto-β-boswellic acid. / Sengupta, Krishanu; Golakoti, Trimurtulu; Marasetti, Ajit K.; Tummala, Tejaswi; Ravada, Suryachandra R.; Krishnaraju, Alluri V.; Raychaudhuri, Siba P.

In: Journal of Food Lipids, Vol. 16, No. 3, 08.2009, p. 325-344.

Research output: Contribution to journalArticle

Sengupta, Krishanu ; Golakoti, Trimurtulu ; Marasetti, Ajit K. ; Tummala, Tejaswi ; Ravada, Suryachandra R. ; Krishnaraju, Alluri V. ; Raychaudhuri, Siba P. / Inhibition of TNFα production and blocking of mitogen-activated protein kinase/NFκB activation in lipopolysaccharide-induced thp-1 human monocytes by 3-o-acetyl-11-keto-β-boswellic acid. In: Journal of Food Lipids. 2009 ; Vol. 16, No. 3. pp. 325-344.
@article{74697d3489b64da1ac404f36c1e64667,
title = "Inhibition of TNFα production and blocking of mitogen-activated protein kinase/NFκB activation in lipopolysaccharide-induced thp-1 human monocytes by 3-o-acetyl-11-keto-β-boswellic acid",
abstract = "Boswellia serrata resin is regarded as a potent anti-inflammatory agent in traditional and herbal medicine in the Indian subcontinent. The compound 3-O-acetyl-11-keto-β-boswellic acid (AKBA) is the most effective boswellic acid and mostly responsible for B. serrata's anti-inflammatory properties. Here, we reexamined the anti-inflammatory potential of a product selectively enriched with 30{\%} AKBA (BE-30, also known as 5-Loxin{\circledR}) and evaluated its underlying possible molecular mechanism of action. BE-30 was 42.96{\%} more effective than regular Boswellia extract (BE-3) in inhibiting 5-lipoxygenase activity. In lipopolysaccharide (LPS)-induced THP-1 human monocytes, BE-30 showed a strong anti-TNFα activity (half maximal inhibitory concentration 4.61 ± 0.87 ̄g/mL), which provides 71.14{\%} (P < 0.001) better efficacy than BE-3. Our investigations suggest that BE-30 inhibits the LPS-induced activation of serine/threonine kinases of mitogen-activated protein kinase family, which are the key players responsible for a variety of cellular responses, including inflammation. Additionally, we also show that BE-30 blocks the LPS-induced NFκB activation by inhibiting IκBα phosphorylation and p65 translocation to the nuclear compartment of THP-1 monocytes. Collectively, these findings provide molecular basis for the anti-inflammatory properties of BE-30. PRACTICAL APPLICATIONS This article describes the underlying molecular mechanisms for the anti-inflammatory activities of an enriched formulation containing up to 30{\%} 3-O-acetyl-11-keto- β-boswellic acid (AKBA), the active principle that is mainly responsible for Boswellia serrata's anti-inflammatory properties. This AKBA-enriched formulation (BE-30), known as 5-Loxin, is commercially available in the United States and is being used as a key ingredient of several formulations for improvement of joint health. This work explains anti-TNFα properties of BE-30 in a cellular inflammation model in vitro and its inhibitory action on MAPK pathways in inflammation and, in addition, its anti-NFκB activities. The findings will provide a further comprehensive mechanism of anti-inflammatory action of 5-Loxin at the cellular and molecular level.",
author = "Krishanu Sengupta and Trimurtulu Golakoti and Marasetti, {Ajit K.} and Tejaswi Tummala and Ravada, {Suryachandra R.} and Krishnaraju, {Alluri V.} and Raychaudhuri, {Siba P}",
year = "2009",
month = "8",
doi = "10.1111/j.1745-4522.2009.01150.x",
language = "English (US)",
volume = "16",
pages = "325--344",
journal = "Journal of Food Lipids",
issn = "1065-7258",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Inhibition of TNFα production and blocking of mitogen-activated protein kinase/NFκB activation in lipopolysaccharide-induced thp-1 human monocytes by 3-o-acetyl-11-keto-β-boswellic acid

AU - Sengupta, Krishanu

AU - Golakoti, Trimurtulu

AU - Marasetti, Ajit K.

AU - Tummala, Tejaswi

AU - Ravada, Suryachandra R.

AU - Krishnaraju, Alluri V.

AU - Raychaudhuri, Siba P

PY - 2009/8

Y1 - 2009/8

N2 - Boswellia serrata resin is regarded as a potent anti-inflammatory agent in traditional and herbal medicine in the Indian subcontinent. The compound 3-O-acetyl-11-keto-β-boswellic acid (AKBA) is the most effective boswellic acid and mostly responsible for B. serrata's anti-inflammatory properties. Here, we reexamined the anti-inflammatory potential of a product selectively enriched with 30% AKBA (BE-30, also known as 5-Loxin®) and evaluated its underlying possible molecular mechanism of action. BE-30 was 42.96% more effective than regular Boswellia extract (BE-3) in inhibiting 5-lipoxygenase activity. In lipopolysaccharide (LPS)-induced THP-1 human monocytes, BE-30 showed a strong anti-TNFα activity (half maximal inhibitory concentration 4.61 ± 0.87 ̄g/mL), which provides 71.14% (P < 0.001) better efficacy than BE-3. Our investigations suggest that BE-30 inhibits the LPS-induced activation of serine/threonine kinases of mitogen-activated protein kinase family, which are the key players responsible for a variety of cellular responses, including inflammation. Additionally, we also show that BE-30 blocks the LPS-induced NFκB activation by inhibiting IκBα phosphorylation and p65 translocation to the nuclear compartment of THP-1 monocytes. Collectively, these findings provide molecular basis for the anti-inflammatory properties of BE-30. PRACTICAL APPLICATIONS This article describes the underlying molecular mechanisms for the anti-inflammatory activities of an enriched formulation containing up to 30% 3-O-acetyl-11-keto- β-boswellic acid (AKBA), the active principle that is mainly responsible for Boswellia serrata's anti-inflammatory properties. This AKBA-enriched formulation (BE-30), known as 5-Loxin, is commercially available in the United States and is being used as a key ingredient of several formulations for improvement of joint health. This work explains anti-TNFα properties of BE-30 in a cellular inflammation model in vitro and its inhibitory action on MAPK pathways in inflammation and, in addition, its anti-NFκB activities. The findings will provide a further comprehensive mechanism of anti-inflammatory action of 5-Loxin at the cellular and molecular level.

AB - Boswellia serrata resin is regarded as a potent anti-inflammatory agent in traditional and herbal medicine in the Indian subcontinent. The compound 3-O-acetyl-11-keto-β-boswellic acid (AKBA) is the most effective boswellic acid and mostly responsible for B. serrata's anti-inflammatory properties. Here, we reexamined the anti-inflammatory potential of a product selectively enriched with 30% AKBA (BE-30, also known as 5-Loxin®) and evaluated its underlying possible molecular mechanism of action. BE-30 was 42.96% more effective than regular Boswellia extract (BE-3) in inhibiting 5-lipoxygenase activity. In lipopolysaccharide (LPS)-induced THP-1 human monocytes, BE-30 showed a strong anti-TNFα activity (half maximal inhibitory concentration 4.61 ± 0.87 ̄g/mL), which provides 71.14% (P < 0.001) better efficacy than BE-3. Our investigations suggest that BE-30 inhibits the LPS-induced activation of serine/threonine kinases of mitogen-activated protein kinase family, which are the key players responsible for a variety of cellular responses, including inflammation. Additionally, we also show that BE-30 blocks the LPS-induced NFκB activation by inhibiting IκBα phosphorylation and p65 translocation to the nuclear compartment of THP-1 monocytes. Collectively, these findings provide molecular basis for the anti-inflammatory properties of BE-30. PRACTICAL APPLICATIONS This article describes the underlying molecular mechanisms for the anti-inflammatory activities of an enriched formulation containing up to 30% 3-O-acetyl-11-keto- β-boswellic acid (AKBA), the active principle that is mainly responsible for Boswellia serrata's anti-inflammatory properties. This AKBA-enriched formulation (BE-30), known as 5-Loxin, is commercially available in the United States and is being used as a key ingredient of several formulations for improvement of joint health. This work explains anti-TNFα properties of BE-30 in a cellular inflammation model in vitro and its inhibitory action on MAPK pathways in inflammation and, in addition, its anti-NFκB activities. The findings will provide a further comprehensive mechanism of anti-inflammatory action of 5-Loxin at the cellular and molecular level.

UR - http://www.scopus.com/inward/record.url?scp=68849118134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68849118134&partnerID=8YFLogxK

U2 - 10.1111/j.1745-4522.2009.01150.x

DO - 10.1111/j.1745-4522.2009.01150.x

M3 - Article

AN - SCOPUS:68849118134

VL - 16

SP - 325

EP - 344

JO - Journal of Food Lipids

JF - Journal of Food Lipids

SN - 1065-7258

IS - 3

ER -